Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo

INTRODUCTION: Chronic lymphocytic leukemia (CLL) is characterized by an aberrant cytokine network that can support tumor growth by triggering janus kinase (JAK)/STAT pathways. Targeting cytokine-signaling should then be a rational therapeutic strategy but the JAK inhibitor ruxolitinib failed to cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Spaner, David E., Luo, Tina YuXuan, Wang, Guizhi, Schreiber, Gideon, Harari, Daniel, Shi, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126367/
https://www.ncbi.nlm.nih.gov/pubmed/37114129
http://dx.doi.org/10.3389/fonc.2023.1043694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126367/
https://www.ncbi.nlm.nih.gov/pubmed/37114129
http://dx.doi.org/10.3389/fonc.2023.1043694

Ejemplares similares